Please login to the form below

Not currently logged in
Email:
Password:

US votes for low cost prescription drug imports

The US House of Representatives has passed a law that will allow the importation of lower-cost prescription drugs from regions outside the US, including Canada, Australia and Europe.

The US House of Representatives has passed a law that will allow the importation of lower-cost prescription drugs from regions outside the US, including Canada, Australia and Europe.

The legislation follows the passing of a USD 91bn spending measure, which funds farm subsidies and nutrition programmes for the budget year starting from October 2007.

The bill faces a veto from President Bush over its price tag, while the administration also opposes the drug importation provision. It says it would effectively permit individuals, wholesalers and pharmacists to import lower cost US-made and FDA-approved prescription drugs from Canada and other countries.

Under current law, US consumers are permitted to buy a 90-day supply in Canada.

Overseas drugs can cost two-thirds less than those in the US, where prices for brand-name drugs are among the highest globally. Outside the US, prices are lower because they are controlled by government regulation.

The White House says there is no system in place to protect consumers from counterfeit or unsafe drugs, but an administration policy statement stops short of an outright veto threat.

A move supported by drug companies to strike the drug importation provisions from the bill was defeated 283-146.

3rd August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics